All Immuno-oncology articles
-
BusinessFully synthetic proteins make tailored medicines
Bright Peak Therapeutics makes modified protein drugs from scratch
-
ResearchDroplet screening set to accelerate immunotherapies into the clinic
Single-cell technique eliminates inefficiencies when identifying immune cells active against specific cancers
-
BusinessBristol-Myers Squibb to buy Celgene for $74 billion
Deal boosts BMS’s cancer and immunology pipeline with 5 drugs in late stage clinical trials
-
OpinionPassing through checkpoints
A new breed of cancer treatments highlights what’s possible when industry concentrates its efforts
-
BusinessCancer immunotherapy spreads rapidly
New approvals and expanded use for checkpoint inhibitor drugs illustrate the power of Nobel-winning science
-
NewsImmune-stimulating cancer treatment takes 2018 medicine Nobel
James Allison and Tasuku Honjo receive science’s highest honour for discovering how cancer stops immune cells from attacking
-
BusinessEurope opens gates to CAR-T
First two modified T-Cell cancer therapies approved in the EU, but prices may be prohibitive for public health systems
-
BusinessBMS stimulates cancer drug hopes with giant collaboration
Immunooncology pioneer will pay up to $3.6bn in hope Nektar drug will help non-responders
-
BusinessCelgene takes a punt on M&A
Cancer specialist bags Juno therapeutics and Impact Biomedicines
-
BusinessUS to invest $160m in cancer partnership
Funds will be backed up with $55m from 11 companies to advance new cancer treatments that harness the immune system
-
-
BusinessBristol-Myers Squibb bags immunotherapy unicorn
Deal will add to pharma giant’s cancer portfolio
-
BusinessAstraZeneca shares tumble after antibody failure
Imfinzi and tremelimumab checkpoint inhibitor pairing fails to beat chemotherapy in lung cancer
-
BusinessNovartis coasts towards first CAR-T approval
Unanimous recommendation for CTL019 ahead of October decision builds confidence in T-cell genetic reprogramming
-
BusinessCelgene and BeiGene agree cancer partnership
Immuno-oncology deal sees firms exchange licensing rights for antibody drugs
-
BusinessFirst biomarker-driven approval exemplifies cancer immunotherapy progress
Landmark decision is latest step in field’s impressive – but not wholly untroubled – advance
-
BusinessExpanding precision medicine beyond cancer
Exclusive interview with Koustubh Ranade, vice president of R&D at MedImmune
-
BusinessMerck & Co settles cancer antibody patent dispute
US firm will pay Bristol-Myers Squibb and Ono $625m plus royalties on future sales of immunotherapy
-
BusinessBoehringer Ingelheim sheds more jobs in the US
Over 240 staff to go as company refocuses on immuno-oncology
-
BusinessNovartis reshuffle puts 120 staff at risk
Commitment to gene and cell therapy treatments emphasised as unit broken up amid pharmaceutical division refocus